It combines three peptides: Palmitoyl Tripeptide-5, Hexapeptide-9, and Hexapeptide-11.
Palmitoyl Tripeptide-5 supports collagen synthesis and inhibits its degradation, while Hexapeptide-9 strengthens the dermal-epidermal junction and promotes epidermal differentiation.
Hexapeptide-11 boosts hyaluronic acid production and further inhibits collagen breakdown, enhancing skin elasticity and reducing wrinkles.
Utilizing a supramolecular delivery system, ActiTide Bouncera ensures deep peptide penetration and optimized bioavailability, effectively targeting the dermis for comprehensive anti-aging results. This technology alleviates collagen loss, diminishes fine lines, and restores skin firmness.
Experimental studies show that ActiTide Bouncera upregulates the gene expression of Collagen IV and VII, strengthening the dermal-epidermal junction and restoring skin support.
At a 0.15% concentration, it promotes Type I collagen synthesis by 332.32%, demonstrating its potential for wrinkle reduction and skin firming.
Furthermore, ActiTide Bouncera significantly inhibits MMP-1, an enzyme that degrades collagen.
At concentrations of 0.10%, 0.06%, and 0.02%, MMP-1 levels were reduced by 94.66%, 88.65%, and 82.35%, respectively, outperforming Vitamin C in the control group.
These results confirm ActiTide Bouncera’s strong anti-wrinkle efficacy and its ability to promote skin rejuvenation.
